Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation

Zhihui Dou 1,2,3,4, Dapeng Zhao 1,2,3,4, Xiaohua Chen 1,2,3,4, Caipeng Xu 1,2,3,4, Xiaodong Jin 1,2, Xuetian Zhang 1,2,3,4, Yupei Wang 5, Xiaodong Xie 6, Qiang Li 1,2,3,4,7, Cuixia Di 1,2,3,4,7* and Hong Zhang 1,2,3,4,7*

Abstract

Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splicing is implicated in genesis and development of multiple human diseases, especially cancers. Exploring the mechanism of Bcl-x splicing and regulation has provided insight into the development of drugs that could contribute to sensitivity of cancer cells to death. On this basis, we review the multiple splicing patterns and structural characteristics of Bcl-x. Additionally, we outline the cis-regulatory elements, trans-acting factors as well as epigenetic modifications involved in the splicing regulation of Bcl-x. Furthermore, this review highlights aberrant splicing of Bcl-x involved in apoptosis evade, autophagy, metastasis, and therapy resistance of various cancer cells. Last, emphasis is given to the clinical role of targeting Bcl-x splicing correction in human cancer based on the splice-switching oligonucleotides, small molecular modulators and BH3 mimetics. Thus, it is highlighting significance of aberrant splicing isoforms of Bcl-x as targets for cancer therapy.

Keywords: Bcl-x, Alternative splicing, Cell apoptosis, Splicing correction, Splice-switching oligonucleotides, Small molecular modulators

Background

Apoptosis regulator Bcl-extra (Bcl-x), also named BCL2L or BCL2L1, is a typical example of apoptotic response gene impacted by splicing. It is an essential member of B-cell lymphoma 2 (Bcl-2) apoptosis family that regulates cell fate [1, 2]. Bcl-x nascent transcripts are alternatively spliced and mainly encode two antagonistic isoforms. The long isoform Bcl-xL blocks apoptosis by inhibiting pro-apoptotic counterparts of Bcl-2 family, whereas the short isoform Bcl-xS can promote apoptosis [2]. An increasing body of data suggests that dysregulated expression of Bcl-x apoptotic isoforms contributes to multiple hallmarks of human cancers. For example, Bcl-xL level was strongly enhanced in cancer cells at the invasive forefront of human breast carcinomas and simultaneously acquired resistance to apoptotic stimuli [3, 4]. However, Bcl-xS conferred the therapeutic sensitivity by decreasing the apoptosis threshold [5]. The ratio of pro-apoptotic Bcl-xS and anti-apoptotic Bcl-xL proteins plays a vital role in regulating the switch between cell life and death. Hence, in this review, we summarize the patterns and the splicing regulatory network of Bcl-x pre-mRNA splicing. In addition, we describe how this aberrant splicing impacted apoptosis, autophagy, invasion and metastasis, immune response, as well as clinical therapy resistance in cancer. Furthermore, we outline the emerging strategies that modulate the cancerous Bcl-x splicing and restore the balance of Bcl-xL/Bcl-xS.
Bcl-xS ratio. Targeting the oncogenic splicing of Bcl-x is believed to result in sensitized cell death by simultaneously blocking Bcl-xL and enhancing Bcl-xS splicing [6].

**Splicing isoforms of Bcl-x**

Alternative splicing expands the coding capacity of genomes of eukaryotes significantly through splice site selection (Fig. 1) [7]. Nearly >95% of human multi-exonic genes could be alternatively spliced into mRNAs isoforms [8]. Splicing reaction is orchestrated by a highly dynamic ribonucleoprotein complex known as spliceosome and hundreds of related proteins [9]. The spliceosome recognizes and assembles reversibly on pre-mRNA to catalytic splicing in a stepwise manner. This process is further modulated by a number of cis-acting elements and trans-acting factors (splice factors) bound to them [9]. Indeed, mutations in cis-regulatory sequences and spliceosomal associated proteins are enriched in cancer. These mutations always affect the splicing of cancer-related genes [10, 11]. A growing body of evidence has revealed aberrant splicing events as contributors of hallmarks of tumorigenesis, such as proliferation, angiogenesis, invasion and apoptosis (Fig. 1) [11, 12].

Bcl-x, a critical apoptotic gene of the Bcl-2 family, is located in chromosome 20 (20q11.1). It was first discovered by using Bcl-2 fluorescent probe hybridization in chickens [2]. Subsequently, two antagonistic isoforms of Bcl-x pre-mRNA in human body were isolated, which then were identified as Bcl-xL and Bcl-xS, respectively. Splicing selection closer to the proximal 5’ splice site (5’PSS) of exon 2 resulted in the long anti-apoptosis isoform Bcl-xL (Fig. 2a), which contained four exons and was composed of 780 bp. The primary structure of Bcl-xL is composed of 233 aa, which contains C-terminal hydrophobic transmembrane (TM) domain responsible for the anchoring to membranes and all four BH domains (BH1-4) (Fig. 2b,c). When the splicing occurred near the cryptic distal 5’ splice site (5’ DSS) of exon 2, the short isoform pro-apoptotic Bcl-xS with 591 bp was produced. Stable Bcl-xS expression played an important role in regulating the ability of pro-survival genes to inhibit apoptotic cell death [2]. Bcl-xS protein is encoded by 170 aa containing both BH3, BH4, and TM domains but lacking BH1 and BH2 domains, which might lead to alternation of hydrophobicity. In addition, other splice isoforms encoded by Bcl-x also had been identified in different cell types and performed diverse functions (Fig. 2b) [13–17]. Despite multiple isoforms that Bcl-x could splice, the pro-apoptotic Bcl-xS and anti-apoptotic

---

**Fig. 1** Alternative splicing and the effect of aberrant alternative splicing on cancer progression. The spliceosome, consists of five small nuclear ribonucleoproteins particles (U1, U2, U4, U5 and U6) and hundreds of additional proteins, recognizes the consensus sequence of each intron and assembles reversibly on splice sites to catalytic pre-mRNA splicing. SR proteins and hnRNPs bound to exonic or intronic regulatory elements to promote or prevent the use of splice sites thus affecting alternative splicing decisions. The figure displays some examples of cancer-specific splicing events that contribute to distinct hallmarks of cancer. Arrows up and down indicate the corresponding isoforms contributing or suppressing the hallmark respectively.
Bcl-xL are still the predominant isoforms acting in cell fate.

Regulation of Bcl-x pre-mRNA splicing

Cis-regulatory elements

Cis-regulatory elements are short nucleotide motifs within pre-mRNA transcripts that providing binding sites for specific trans-acting factors. It can be categorized into exonic splicing enhancers (ESEs), exonic splicing silencers (ESSs), intronic splicing enhancers (ISEs) and intronic splicing silencers (ISSs) depending on their position and impact on the use of splice site [18]. Bcl-x pre-mRNA contains several cis-elements acting as splicing activators or repressors by interacting with related splicing factors (Fig. 2a). For example, SB1 (361bp), located in the first half of exon 2, was defined as an ESE because splicing to Bcl-xS was even stronger in the absence of SB1. Similarly, DNA damage-induced Bcl-xS splicing only increased in the presence of SB1 [19]. In addition, B1 was a composite element located upstream of 5’ DSS of Bcl-x pre-mRNA. The 5’ portion of B1 displayed ESE activity, whereas the 3’ portion was occupied with ESS element. hnRNP K bound to the silencer portion of B1 to repress the production of Bcl-xS [20]. Moreover, B2G module was a 30-nucleotides G-rich element located immediately downstream of the 5’ DSS. Combination of hnRNP F/H to B2G enhanced Bcl-xS splicing. B3 located upstream of 5’PSS to favor the production of Bcl-xL. The two elements ML2 and AM2 within B3 were identified to enhance Bcl-xL splicing through interacting with SRp30c [21]. Deleting B2G and B3 regions completely abrogated production of Bcl-xS and Bcl-xL respectively [22]. Another two cis-elements CRCE1 and CRCE2 within exon 2 were essential for ceramide-responsive Bcl-x expression. Mutation of CRCE1 or CRCE2 induced a decreased ratio of Bcl-xL/Bcl-xS [23]. In addition to exonic elements, the intron region downstream from Bcl-xL 5’PSS also had been identified to mediate signals from extracellular factors such as interleukin-6.

![Fig. 2 Bcl-x pre-mRNA splicing and structures of splicing isoforms.](image)
and granulocyte-macrophage colony-stimulating factor (GM-CSF) to repress Bcl-xL splicing [24].

**Trans-acting factors**

A variety of trans-acting factors are involved in the formation of splicing regulatory network, including SR proteins, hnRNPs as well as some transcription factors (Fig. 2a) [25]. Posttranslational modifications of splicing factors would also change their binding state to cis-elements. For example, Sam68 bound to Bcl-x pre-mRNA specifically and recruited hnRNP A1 to a particular region, which caused the selection of Bcl-xS in a dose-dependent manner. This favor could be inverted by tyrosine phosphorylation of Sam68 [26]. In addition, SRSF1 was known to compete with hnRNPA1 to promote Bcl-xL splicing. However, the activity of SRSF1 itself was antagonized by splicing factors RBM4 and PTBP1 [27, 28]. Moreover, a multicomponent regulatory hub consisting of SRSF10, hnRNP A1/A2, and Sam68 was reported to activate the 5’DSS of Bcl-x in response to DNA damage [29]. Because alternative splicing is coupled to transcription, a large number of transcription factors were found to influence splicing selection. For instance, E2F1 was suggested to increase Bcl-xS isoform through upregulating SRSF2 [30]. FB1–1 could interact with the full length or C-terminal domain of Sam68 to counteract Sam68-mediated apoptosis [31]. Moreover, TCERG1 [32], FOXP3 [33], ETS [34] as well as cellular signal pathways and other regulatory modes such as exon junction complex, G-rich sequences were all involved in Bcl-x splicing and had been summarized in Table 1 (Table 1).

**Epigenetic modifications**

Epigenetic modifications had been suggested to interplay intricately with alternative splicing [49]. It had been reported that DNA methylation at exons and splicing sites were involved in over 20% splicing modulation by regulating the elongation rate of RNA polymerase II primarily [50]. In other studies, the dynamic histone acetylation mark of H3K4me3 nucleosome played a critical role in Mcl-1 pre-mRNA splicing [51]. Moreover, N6-methyladenosine modification was indicated to regulate splicing by co-localization with splice sites and reshaping the structure of pre-mRNA [52]. However, there were poor reports about whether and how the epigenetic modifications mentioned above affected the splicing decision of Bcl-x pre-mRNA. To date, ncRNA was the most common epigenetic regulation identified to influence Bcl-x splicing that functions as ‘interactors’ or ‘hijackers’ of splicing factors [49]. LncRNA BC200, LINC00162 as well as LncRNA-HEIH had been shown to modulate Bcl-x pre-mRNA splicing effectively [53–55]. To investigate the splicing mechanism regulated by ncRNA in-depth is necessary.

**The function of aberrant Bcl-x splicing in cancer Apoptosis**

Apoptosis, characterized by a series of morphological alternations including cell shrinkage, pyknosis and karyorrhexis, plasma membrane blebbing and apoptotic body formation, is a mechanism for all multicellular organisms to modulate cell life development [56]. Abnormalities in apoptosis play a crucial role in the progression of various human disease like cancer [57]. Therefore, targeting apoptotic pathways has been a mainstay for the cancer drug discovery and development. There are two commonly established apoptotic pathways in mammals: the extrinsic pathway of apoptosis mediated by the death receptor and the intrinsic pathway of apoptosis mediated by mitochondria [58]. The extrinsic apoptotic signal begins when extracellular death-inducing factors bind to its receptors (TNFR, TRAIL, FasL), recruiting adapter proteins (TRADD, FADD, caspase 8 and/or caspase 10) to form the death inducing signaling complex [59]. The intrinsic apoptotic pathway is closely regulated by the Bcl-2 family proteins. Bcl-2 proteins mainly were divided into three subgroups up to their BH domain: BH3 only proteins to initiate apoptosis (Bim, Bad, Bid, Noxa, Bmf, Hrk, Bik, Puma), pro-apoptotic proteins act as apoptotic executioner (Bax, Bak, Bok) and anti-apoptotic subfamily (Bcl-2, Bcl-xL, Bcl-W, A1, Bcl-B, Mcl-1) [60]. Initiated by internal stimuli such as DNA damage, hypoxia and oxidative stress, activated-BH3 only proteins inhibit the anti-apoptotic Bcl-2 proteins. Subsequently, activated and oligomerized Bax/Bak located in the mitochondrial outer membrane, promoting mitochondrial outer membrane permeability (MOMP), the release of cytochrome C and caspase activation [61]. Disruption in the balance of pro-apoptotic and anti-apoptotic members of the Bcl-2 family proteins promotes carcinogenesis and cancer cell survival [62]. More importantly, anti-apoptotic Bcl-2 proteins are widely over-expressed in cancers and have been established to contribute to therapy resistance, recurrence and poor prognosis [63, 64].

Alternative splicing of Bcl-x pre-mRNA is one of the earliest oncogenic splicing events critical for apoptotic responses of cancer cells. The elevated level of Bcl-xL caused by aberrant splicing has been revealed in a multitude of human cancers and is considered to be a powerful driving force for cell apoptotic resistance (Table 2) [1, 78]. Instead, cells with highly expressed Bcl-xS were more sensitive to apoptosis stimuli [25]. Structural features enabled Bcl-xL to bind to its natural ligands, such as pro-apoptotic Bcl-2 family members that respond to a variety of cellular stimuli [64]. This process had been well documented by the tertiary structure of Bcl-xL/BH3...
peptides, that pro-apoptotic BH3 peptide bound to the hydrophobic groove of Bcl-xL via hydrophobic and electrostatic interactions [88]. In general, Bcl-xL distributed on the intracellular membrane appeared to regulate apoptosis mainly by three modes. In mode 0, Bcl-xL could prevent the binding of apoptotic effectors Bax to mitochondrial outer membrane through retrotranslocating Bax from the mitochondria into cytosol constantly (Fig. 2a) [89]. In mode 1, Bcl-xL could sequester BH3-only activators (For example Bid truncated in the death receptor-mediated pathways (Fig. 3b)) to prevent them from binding to and activating Bax (Fig. 3a). In mode 2, Bcl-xL was suggested to directly bind to activated Bax to prevent its oligomerization and pore formation, which prevented the release of caspase activator from mitochondrial outer membrane (Fig. 3a) [90]. However, Bcl-xL sequestration could be derepressed by sensitizer BH3 only proteins (For example Bad), which then induced activation of Bax and MOMP (Fig. 3b) [90]. Bogner et al. suggested that the allosteric regulation by Bcl-xL complexes might play an important role in this process [91]. Moreover, Bcl-xL was suggested to inhibit a weak Bax activation and apoptotic signal via directly sequestrating active cytosolic p53 induced by damage stimuli (Fig. 3b) [92]. The above demonstrated that apoptosis decision of cells was dependent on the relative abundance of Bcl-xL and its pro-apoptotic counterparts [64, 90]. In addition to the already established roles in mitochondrial apoptotic pathways, Bcl-xL was proved to function as an inhibitor of VDAC1 to prevent apoptosis induced by excessive Ca^2+ transferred from endoplasmic reticulum to mitochondria (Fig. 3b) [93]. Thus it is imperative to

| Regulation methods | Mechanism | Selection | Ref |
|-------------------|-----------|-----------|-----|
| RNA binding proteins | Sam68 | Recruit hnRNP A1 to certain regions. | Bcl-xS | [26] |
| | SRSF1 (ASF/SF2) | Compete with hnRNP A1. | Bcl-xL | [26, 35] |
| | SRSF10 | Collaborate with hnRNP A1/A2 and Sam68. | Bcl-xS | [29] |
| | SRSF2 (SC35) | As a direct transcriptional target of E2F1. | Bcl-xS | [30] |
| | SRSF3 | Favor the selection of the 5’ DSS. | Bcl-xS | [28] |
| | SRSF7 | Favor the selection of the 5’ DSS. | Bcl-xL | [28] |
| | SRSF9 (Sp30c) | Bind to ML2 and AM2. | Bcl-xL | [21] |
| | TRA2β | Favored selection of the 5’ DSS. | Bcl-xS | [28] |
| | hnRNP F/H | Bind to B2G region. | Bcl-xS | [22, 36] |
| | PTBP1 (hnRNP I) | Bind to polypyrimidine to promote 5’ DSS selection | Bcl-xS | [28] |
| | hnRNP A1 | Interact with Sam68. | Bcl-xS | [25, 26] |
| | hnRNP A2/B1 | Regulated by Fyn activity. | Bcl-xL | [39] |
| | hnRNP K | Bind to silencer element of the 5’ DSS. | Bcl-xL | [20] |
| | RBM4 | Antagonize oncogenic SRSF1. | Bcl-xS | [38] |
| | RMB10 (S1-1) | Block the GGGAUAAG of exon 2. | Bcl-xS | [39] |
| | RBM11 | Antagonize SRSF1. | Bcl-xS | [40] |
| | RMB25 | Bind to CCGGUA sequence within exon 2. | Bcl-xS | [41] |
| Transcription factors | E2F1 | Upregulate SC35 protein expression. | Bcl-xS | [30] |
| | FBI-1 | Interact with Sam68 and affects its binding. | Bcl-xL | [31] |
| | TCERG1 | Increase the elongation rate of RNAPII. | Bcl-xS | [32] |
| | FOXP3 | Repress hnRNPF binding to 5’DSS. | Bcl-xL | [33] |
| | SAP155 (SF3B1) | Bind to CRCE 1 region. | Bcl-xL | [42] |
| Signal pathway | PKC signal | Through SB1 to repress the 5’DSS splicing. | Bcl-xL | [43] |
| | PI3K/PKC, signal | Regulate SAP155-CRCE1 complex formation. | Bcl-xL | [44] |
| | LPS/PRMT2 or TNF-α pathway | Interact with Sam68 and regulate its subcellular localization via its SH3 domain. | Bcl-xL | [45] |
| G4s and G4s ligands | G-quadruplexes (G4s) | Close to the two alternative 5’SS to compete with other RNA structures or proteins | Bcl-xS or Bcl-xL | [46, 47] |
| | G-quadruplex ligands (GQC05) | Stabilize G-quadruplexes. | Bcl-xS | [46] |
| EJC | Exon junction complex ( EJC ) | RNPS1 and core EJC proteins control Bcl-x splicing through cis-acting elements SB1. | Bcl-xL | [48] |
investigate the in-depth mechanism that Bcl-xL used to coordinate apoptotic signals from multiple pathways and ultimately, form an integrated perspective. Compared to Bcl-xL, the short isoform Bcl-xS was reported as a negative regulator of survival because it could inhibit the function of Bcl-xL by forming heterodimers with Bcl-xL through the BH3 domain, or disrupting the VDAC2-Bak complex to cause the release of Bak and activation of MOMP (Fig. 3b) [94, 95]. Furthermore, Bcl-xS induced activation of Bak and promoted apoptosis through apoptosome-dependent and independent pathways [96]. Therefore, the antagonistic roles played by Bcl-x isoforms were critical for cell fate decision. Alternative splitting regulation of Bcl-x to promote Bcl-xS but inhibit Bcl-xL splicing could act as a tumour suppression strategy. For instance, Src family kinase Fyn was found to decrease the phosphorylation of Sam68 but regulate hnRNPA2/B1 expression, which synergistically promoted the splicing of Bcl-xL and inhibited apoptosis of pancreatic cancer cells. Fyn inhibition down-regulated hnRNPA2/B1 expression and increased Bcl-xS splicing [37]. In addition, study on human liver fibrosis suggested that Bcl-xL was preferentially spliced in human hepatic stellate cells and consistent with apoptosis resistance of HSCs. Antisense oligonucleotides inhibiting Bcl-xL splicing induced HSC cell apoptosis [97]. Interestingly, the IE86 gene of human cytomegalovirus was found to inhibit apoptosis and promote proliferation of glioma cells by enhancing the favor splicing of Bcl-xL mediated by hnRNPA2/B1 [98]. Thus, the favored use of 5’PSS splice site in Bcl-x pre-mRNA contributes to the escape of cancer cells from intrinsic programmed apoptosis.

**Autophagy**

In addition to apoptosis, the long isoform Bcl-xL also had been suggested to be involved in autophagy, which was an evolutionarily conserved pathway and played a double-edged role in tumour progression [84]. A recent study explored that Bcl-xL could inhibit PINK1/Parkin-dependent mitophagy through directly interacting with Parkin and PINK1 to inhibit the translocation of Parkin from cytoplasm into mitochondria (Fig. 4) [99]. More importantly, Bcl-xL was identified to hinder macroautophagy mediated by class III PI3K pathway through direct interactions with Beclin-1, a new BH-3 only protein that is essential to regulate the initial of autophagy

**Table 2** Aberrant Bcl-x splicing in cancers and its clinical application

| Cancer type          | Bcl-xL/S | Function                                                                 | Ref  |
|----------------------|----------|--------------------------------------------------------------------------|------|
| Apoptosis            |          |                                                                          |      |
| Hepatocellular Carcinomas | Bcl-xL↑   | Inhibit apoptosis initiated by cellular stimuli [65]                     |      |
| Colorectal cancer (CRC) | Bcl-xL↑   | Drive tumourigenesis and progression.                                     [66] |
| Breast cancer        | Bcl-xL↑   | Suppress BETi-induced apoptosis.                                         [67]  |
| Meningioma           | Bcl-xL↑   | Contribute to apoptosis induced by Dovitinib.                             [68]  |
| Malignancy            |          |                                                                          |      |
| Gastric cancer       | Bcl-xL↑   | Associated with high Beclin1 expression.                                  [69]  |
| Tongue Carcinoma     | Bcl-xL↑   | Related to the degree of differentiation.                                 [70]  |
| Hodgkin lymphoma     | Bcl-xL↑   | Consistent with the severity of patients.                                 [71]  |
| Myeloproliferative neoplasms | Bcl-xL↑   | Progressively over-expressed.                                             [72]  |
| Lymphomas            | Bcl-xL↓   | Expressed by malignant cells.                                             [73]  |
| Wilms’ tumours       | Bcl-xL↓   | Negatively correlated with tumour stage.                                  [74]  |
| Endometrial carcinoma| Bcl-xL↓   | Correlated with pathological grading.                                    [75]  |
| Metastasis            |          |                                                                          |      |
| Pancreatic cancer     | Bcl-xL↑   | Promote metastasis                                                       [76]  |
| Glioblastoma         | Bcl-xL↑   | Promote cell migration, invasion, angiogenesis and stemness.             [77]  |
| Melanoma              | Bcl-xL↑   |                                                                          [77]  |
| Drug-resistance       |          |                                                                          |      |
| Chondrosarcoma       | Bcl-xL↑   | Confer resistance to chemotherapy.                                       [78]  |
| Ewing sarcoma        | Bcl-xL↑   | Resistant to olaparib.                                                   [79]  |
| Ovarian carcinoma (OC)| Bcl-xL↑   | Confer resistance to chemotherapy.                                       [80]  |
| Hepatocellular carcinoma | Bcl-xL↑   | Chemoresistance and poor prognosis.                                      [81]  |
| Urothelial Carcinoma  | Bcl-xL↑   | Effectively inhibited cisplatin-resistant UCs.                            [82]  |
| Radiation             |          |                                                                          |      |
| laryngeal cancer      | Bcl-xL↑   | Associated with radiosensitive.                                           [83]  |
| Non-small cell lung cancer | Bcl-xL↑   | Enhance irradiation resistance.                                           [84]  |
| Prostate cancer       | Bcl-xL↑   | Enhance survival to cells exposed to IR.                                  [85]  |
| Osteosarcoma          | Bcl-xL↑   | Enhance irradiation resistance.                                           [86]  |
| Malignant pleural mesothelioma | Bcl-xL↑   | Negatively associated with radiosensitivity.                             [87]  |
Low expressed Beclin-1 but highly expressed Bcl-xL is consistent with malignant phenotype and poor prognosis of cancer [69, 102]. Bcl-xL physically interacted with BH3 domain of Beclin-1 and disrupted hVps34–Beclin-1 complex which stimulated autophagosomes formation (Fig. 4) [103, 104]. BH3 mimetics and overexpressed BH3-only proteins could displace Beclin-1 from Bcl-xL and stimulate autophagy. Intriguingly, Beclin-1 was reported to induce apoptosis of glioblastoma cells through binding to Bcl-xL [105], whereas another research
suggested that heterooligomers formed by Bcl-xL and Beclin-1 could maintain full anti-apoptotic function in HeLa cells induced by staurosporine [106]. These results support the model that direct interactions between Bcl-xL and Beclin-1. However, Lindqvist LM et al. suggested that Bcl-xL had no measurable effect on autophagy in the absence of Bax/Bak [107]. When Bax/Bak were present, inhibiting the pro-survival Bcl-2 family members stimulated autophagy and correlated with increased cell death, suggesting that inhibition of Bcl-xL on autophagy was an indirect effect generated from apoptosis inhibition by a yet unknown mechanism. In summary, the possible relevance between apoptosis and autophagy in the process of cell death mediated by Bcl-xL includes:(1) Bcl-xL physically interacts with Beclin-1 to regulate apoptosis and autophagy synergistically or antagonistically; (2) Bcl-xL does not bind to Beclin 1 but instead regulate autophagy by inhibiting Bax/Bak mediated apoptosis [3]. Thus, further research is required to determine the crosstalk between apoptosis and autophagy mediated by Bcl-xL and other Bcl-2 family proteins, which is of great significance for maintaining the overall cell fates.

**Invasion and metastasis**

Bcl-xL had been suggested to contribute to invasion and metastasis in multiple cancer types. After knocking Bcl-xL, the invasive and metastatic phenotype of CRC cells were reduced but did not cause spontaneous cell death [108, 109]. Studies of oral tongue cancer and breast cancer found that Bcl-xL expression was significantly high in metastasis tissue [4, 70]. In transformed human mammary epithelial cells, Bcl-xL directly interacted with RAS to modulate RAS signaling through BH4 domain, which was critical for RAS induced stemness and cancer initiating cell phenotype [110]. In addition, overexpressed Bcl-xL in human melanoma was found to promote vasculogenic structures through CXCL8/CXCR2 pathway. Meanwhile, the increased cancer stem cell markers associated with stemness and aggression of tumour cells (for example HIF-1α, NANOG, OCT4, BMI1, and SOX2) were also observed [111]. Notably, a recent study of Bcl-xL with deficiency in apoptosis suggested that anti-apoptotic function of Bcl-xL might be separated from its roles in the motility of cancer cells. For example, Choi et al. [76] showed that Bcl-xL defected in anti-apoptotic function promoted epithelial-mesenchymal transition (EMT), migration, invasion, as well as stemness of panNET and breast cancer cells. Additionally, Bessou et al. [112] suggested that the complex formed by BH4 domain of Bcl-xL and VDAC1 acted on MOMP to increase ROS in mitochondrial electron transport chain and inhibit the absorption of Ca^{2+}, thereby promoting migration and metastasis of breast cancer cells independently of apoptotic activity. How Bcl-xL regulates the invasion and metastasis of cancer cells independently of apoptosis still needs further exploration.

**Anti-tumor immunity**

Anti-apoptotic Bcl-xL has been demonstrated to play a key role in the survival of immune cells and immune responses. Grillot et al. has reported that Bcl-xL is highly expressed in CD4+ CD8+ thymocytes which exhibited increased viability in vitro [113]. Enforced Bcl-xL expression could also restore the development of splenic B Lymphocyte [114]. In addition, Bcl-xL was proved to promote survival of effector T cells and antigen-bearing dendritic cells [115, 116]. Regulatory T cells showed enhanced suppressive capacity through increasing Bcl-xL expression, which provide a new strategy for treatment of tumours through remodelling regulatory T cells [117]. Surprisingly, Bcl-xL was demonstrated to protect tumour cells from Natural Killer cells-mediated suppression and therefore exerted tumour-progressive activity [118, 119]. However, Andersen et al. suggested highly expressed Bcl-xL of cancer cells were the common target recognized by specific T cells [120]. They also speculated that immune responses against apoptosis inhibitors like Bcl-xL might represent a general feature in cancer [120]. Taken together, there is a complex effect of Bcl-xL expression on anti-tumour immune response. It is of great significance to identify the role of overexpressed Bcl-xL in immune escape of tumor cells.

**Clinical impaction of Bcl-x splicing in cancer Chemotherapy**

Tolerability generated during chemotherapy such as apoptosis escape and Epithelial mesenchymal transformation (EMT), results in poor prognosis and is currently impeding the success of targeted therapies in cancer treatment [121, 122]. Plenty of evidence suggested that Bcl-xL-dependent apoptotic inhibition was the main reason that promoted chemotherapy resistance in tumours in vitro and vivo (Table 2) [123, 124]. A study on breast cancer showed that cells passed through EMT obtained therapeutic resistance by upregulating Bcl-xL transcripts. However, apparent apoptotic resistance was removed after deleting Bcl-xL [4]. Bcl-xL was also found to mediate doxorubicin resistance of breast cancer through the Ring finger protein 6/Estrogen receptor α/Bcl-xL pathway [125]. Inhibiting Bcl-xL expression in breast cancer cells enhanced the cytotoxicity and apoptosis induced by T-DM1 [126]. Additionally, increased CXCR4 expression in ovarian cancer induced cisplatin resistance through promoting Bcl-xL/S [123]. Upregulated Bcl-xL expression was also found to be involved in resistance to therapy targeting Bcl-2 in mantle-cell lymphoma and Acute Myelocytic Leukemia [57, 127]. Regarding melanoma, it
has been demonstrated that forced expression of ectopic Bcl-xL converted drug-sensitive cell lines into drug-resistant ones [128]. However, vivo-Morpholino (vMO) antisense oligomers that used to upregulate Bcl-xS expression but decrease Bcl-xL in chronic myeloid leukemia (CML) increased growth inhibition and apoptotic sensitivity of imatinib mesylate-resistant CML cells [5]. Similarly, overexpressed Bcl-xS in human breast carcinoma cells induced a remarkable increase in sensitivity to chemotherapy agents, but did not affect cell viability by itself [129].

**Radiotherapy**

The splicing favor of Bcl-xL contributed to long-term radiotherapy resistance (Table 2). Clinical data showed that Bcl-xL was expressed by about 91% of laryngeal cancer patients resistant to radiotherapy, suggesting a critical function of Bcl-xL in radiotherapy [83]. Streffer et al. [130, 131] found that glioma cell lines with high Bcl-xL expression had higher ED50 (2.9 ± 0.8Gy) than cell lines with lower Bcl-xL. However, no association with radiosensitivity was observed for the expression levels of Bcl-xS. Highly expressed Bcl-xL was also found to cause radiation resistance of osteosarcoma cells with both low and high metastasis level, and Bcl-xL downregulation could significantly enhance radiation cytotoxicity of osteosarcoma cells [86]. Moreover, inhibiting the expression level of Bcl-xL were suggested to reverse radioresistance and regulate radiation-induced apoptosis of mesothelioma, breast cancer, prostate cancer, colorectal cancer as well as non-small cell lung cancer [84, 87, 132, 133]. In addition to therapeutic effects, irradiation was well known to induce increased invasiveness and metastasis of cancer cells. Ho et al. demonstrated that the expression of Bcl-x was elevated after irradiation, which promoted the malignant actions of lung cancer cells [134]. A recent study also suggested that upregulated Bcl-xL induced invasion of cancer cells that underwent sublethal doses of irradiation by stimulating respiratory complex I and increasing additional ROS production, which might be involved in the local recurrence or distal metastasis of some patients after radiotherapy [135]. Interestingly, the expression of Bcl-xL could enhance energy metabolism and prevent oxidative stress, which might be involved in the alleviation of mitochondrial oxidative stress induced by radiation [136]. In addition, inhibition targeting Bcl-xL/2 had been found to reverse the pulmonary fibrosis induced by ionizing radiation [137]. These results provided a wealth of evidence that inhibition the endogenous expression of Bcl-xL might promote both radiation sensitization and radiation protection. However, combination of γ-irradiation and genetic loss but not pharmacological inhibition of Bcl-xL was found to cause fatal kidney damage and secondary anemia in adult mice, and the underlying mechanism remained unclear [138]. This finding demonstrated the protective role of Bcl-xL in adult kidney, which also represents challenges for the radio-sensitization targeting Bcl-xL.

**Strategies modulating Bcl-x splicing in cancer**

**Splice-switching oligonucleotides**

SSOs, typically 15-30 nucleotides, is a kind of synthetic, modified, steric block antisense oligonucleotides which have been widely used to disrupt the splicing mode of pre-mRNA through Watson-Crick base pairing. The generated steric hindrance but not degradation of targeted transcripts affected accessibility of splicing factors and visibility of spliceosome, which led to splicing isoforms switching ultimately [139]. Notably, natural oligonucleotides had been proved to be quite ineffective due to their defects such as easy to be degraded, lower affinity, and higher off-target effect. Therefore, various chemical modifications on phosphate backbone or ribose rings of SSOs had been developed to allow for improved stability and binding affinity, meanwhile, reduced cytotoxicity and immunogenicity [139]. Common types of oligonucleotides chemistry have been shown in Fig. 5. Notably, the third generation of antisense oligonucleotides was featured by furanose ring modifications of nucleotides including phosphorodiamidate morpholinos (PMOs), locked nucleic acid and peptide nucleic acid. PMOs was a type of neutrally charged nucleic acid. PMOs was a type of neutrally charged nucleic acid, in which the furanose ring was substituted by a morpholine ring while each unit was bridged with a phosphorodiamidate linkage. PMOs usually needed to be conjugated to cell-penetrating peptides or covalently linked to an octaguanidine dendrimer for efficient delivery due to their rapid renal clearance. To date, PMOs modified SSOs drugs eteplirsen and golodirsen had been approved by the FDA for clinical therapy of Duchenne muscular dystrophy and spinal muscular atrophy, respectively [140, 141]. In addition, for effective SSOs of target genes, the optimized length, sequence constitution, secondary structures, accessibility, as well as thermodynamic properties were all critical factors [92]. Generally, SSOs base-paired to the alternative splice site of Bcl-x pre-mRNA could block arrival of spliceosome and binding of splicing factors to their target motif, which led to the redirection of splicing favor (Fig. 6a). Bcl-xSSOs could promote apoptosis and drug sensitivity of cancer cells by correcting Bcl-xL splicing to Bcl-xS efficiently [142]. Some Bcl-xSSOs sequences used in preclinical had been summarized in Table 3. Mercatante et al. proved that endogenous highly expressed Bcl-xL was positively correlated with...
cellular response to Bcl-xSSOs induced splice shift [147], which indicated that normal cells with low expressed Bcl-xL might be more resistant to Bcl-xSSOs therapy. 2′-OMe-PS modified Bcl-xSSOs caused a splice shift from Bcl-xL to Bcl-xS and increased apoptosis of prostate cancer, breast cancer, and hepatic stellate cells [97, 147]. In addition, splice redirection of Bcl-x pre-mRNA induced by 2′-MOE modified Bcl-xSSOs in glioma cells and melanoma xenograft models showed pro-apoptotic effect and reduced tumour load respectively [142, 143]. Moreover, vMO modified Bcl-xSSOs was found to correct aberrant splicing of Bcl-x in CML cells and improve therapeutic sensitivity to imatinib mesylate significantly [5, 148]. Therefore, highly expressed Bcl-xL could be reversed by modified Bcl-xSSOs, which allowed the redirection of aberrant splicing and rebalanced the ratio of Bcl-xL/Bcl-xS [6].

![Diagram of chemical modifications of splice switching oligonucleotides](image)

**Fig. 5** Chemical modifications of splice switching oligonucleotides. **a.** Chemical modifications on phosphate backbone and ribose ring of SSOs. Unmodified RNA is shown for reference. PS, one of the phosphate backbone oxygen atom is replaced by a sulphur atom; 2′-MOE and 2′-OMe, PS-SSOs are often combined with ribose modifications including 2′-O(2-methoxyethyl) or 2′-O-methyl; PMO, charge-neutral nucleic acid, in which the six-membered morpholine ring replaces the five-membered ribose heterocycle; PPMO, positively charged peptides in PPMO dramatically improve intracellular uptake of PMO. VPMO, covalently linking MO to an octaguanidine dendrimer to improve delivery efficacy. LNA, the second and fourth of ribose form a rigid structure by shrinkage. PNA, a pseudo peptide polymer backbone substitutes for the phosphate backbone of RNA. **b.** Properties comparison of the common chemistries of antisense oligonucleotides.
Small molecular modulators redirect Bcl-x splicing
A class of natural or synthetic small molecular modulators had been identified to perform anti-tumour activity through inhibiting the activity of targeted splicing factors (Fig. 6b) [149, 150]. These compounds modulated RNA splicing in two ways generally. One way was to directly target pre-mRNA splicing factors. For example, the crude extract of the South African Medicinal Plant (Cotyledon orbiculata) could induce a splicing shift from Bcl-xL to Bcl-xS and apoptosis of cancer cells [151]. However, it was interesting that Bcl-x exhibited resistance to splicing perturbation induced by SF3B1.

Table 3 Splice switching oligonucleotides used to modulate Bcl-x pre-mRNA splicing

| Cells types     | Sequence            | Length | Chemistry  | Ref  |
|-----------------|---------------------|--------|------------|------|
| K562            | 5'-GCTTGGTCTTACCACCAGCCGCCGT3' | 25 mer | vMO        | [5]  |
| Primary HSCs    | 5'-TGGTTCTTACCACCAGCCGCCG3'  | 20 mer | 2'-OMe-PS  | [97] |
| U87, U251       | 5'-TGGTTCTTACCACCAGCCGCCG3'  | 20 mer | 2'-MOE-PS  | [142]|
| B16F10          | 5'-TGGTTCTTACCACCAGCCGCCG3'  | 20 mer | 2'-MOE-PS  | [143]|
| Human RPE       | 5'-TGGTTCTTACCACCAGCCGCCG3'  | 20 mer | 2'-MOE     | [144]|
| A549            | 5'-CTGGATCCAGGCTCTAGGT3'    | 20 mer | 2'-MOE     | [145]|
| PC-3            | 5'-ACCCACGGCCCGUUCUC3'      | 18 mer | 2'-OMe-PS  | [146]|
| MCF-7           | 5'-ACCCACGGCCCGUUCUC3'      | 18 mer | 2'-OMe-PS  | [146]|
| Hela            | 5'-ACCCACGGCCCGUUCUC3'      | 18 mer | 2'-OMe-PS  | [146]|

---

**Fig. 6** Strategies modulating Bcl-x splicing in cancer. a. An SSO that binds to the proximal 5' splice site (5'PSS) prevents binding of spliceosome, leading to a splicing shift to the short isoform Bcl-xS. b. The small molecular modulators that bind to spliceosomal components affect splice-site accessibility, leading to an inhibition of Bcl-xL splicing. c. At the protein level, BH3-mimetics could occupy the hydrophobic pockets of Bcl-XL, thus blocking their anti-apoptotic activity and resulting in the ignition of apoptosis.
inhibitors E7107. Splicing modulation of E7107 was sensitized after Bcl-xL knockdown, which suggested that Bcl-xL could function as a sensitizing gene or as a biomarker for splicing modulator treatment [152]. The other way was to target kinases that were involved in post-translation modulation of splicing factors. For example, potent protein synthesis inhibitor emetine had been proved to enhance Bcl-xS splicing in a time and dose-dependent manner in multiple cancers, however, this effect could be hindered by protein phosphatase 1 (PP1) [153]. Alkaloid Homo-harringtonine approved for CML treatment by the FDA as well as antihypertensive agent amiloride and its derivatives BS008 were all proved to normalize oncogenic splicing pattern of Bcl-x in cancer cells depending on PP1 activation [154–156]. Intriguingly, Moore et al. found that inhibitors of cell cycle factors aurora kinase A (for example ZM447439 and VX-680) could induce endogenous Bcl-xS splicing significantly, revealing a complex alternative splicing network coordinating cell cycle and apoptosis [157]. In general terms, studying the mechanism of splice switch induced by small molecular modulators is essential for splicing therapies and antitumour agent discovery based on splicing correction. Notably, although the effectiveness that small molecules showed in splicing modulation, they usually lacked specificity and caused off-targeted or on-targeted cytotoxicity.

Table 4 Clinical application of BH3-mimetics targeting anti-apoptotic Bcl-2 family proteins. (clinicaltrials.gov)

| Multiple targets | Compounds | Origin | Stage | Ref |
|------------------|-----------|--------|-------|-----|
| Bcl-xL           | A-1155463 | Structure-based design. | Preclinical | [159] |
|                  | A-1331852 | Structure-based design. | Preclinical | [160] |
|                  | WEHI-539  | Structure-based design | Preclinical | [161] |
|                  | DT2216    | Proteolysis targeting chimera | Preclinical | [162] |
|                  | XZ424     | Proteolysis targeting chimera | Preclinical | [163] |
|                  | ABBV-155  | Structure-based design | Phase I | NCT03595059 |
|                  | AZD4320   | Structure-based design | Preclinical | [164] |
|                  | BM-957    | Structure-based design | Preclinical | [165] |
|                  | BM-1197   | Structure-based design | Preclinical | [166] |
|                  | S44563    | Structure-based design | Preclinical | [167] |
|                  | APG-1252  | Structure-based design | Phase I/II | [168] |
|                  | Ch282-5   | Gossypol derivative | Preclinical | [169] |
|                  | ABT-737   | Synthetic, acylsulfonamide-based | Phase I/II/III | [170] |
|                  | ABT-263 (Navitoclax) | Derivant of ABT-737 | Phase I/II/III | [171] |
|                  | BH3-M6    | Synthetic terphenyl scaffold | Preclinical | [172] |
|                  | TW-37     | Benzenesulfonyl derivative of gossypol | Preclinical | [173] |
|                  | Bi-97C1 (Sabutoclax) | Prostereoisomer of Apogossypol | Preclinical | [174] |
|                  | BIM-SAHB  | Stapled Bim peptide | Preclinical | [175] |
|                  | GX15-070 (Obatoclax) | Synthetic indolyl-dipyromethene | Phase I/II/III | [176] |
|                  | AT-101    | (−)-gossypol enantiomer | Phase I/II/III | [177] |
|                  | S55746    | Structure-based design | Phase I | [178] |
|                  | ABT-199 (Venetoclax) | Derivant of ABT-263 | Phase I/II/III | [127] |
|                  | A-1210477 | Structure-based design | Preclinical | [179] |
|                  | UMI-77    | Structure-based design | Preclinical | [180] |
|                  | VIJ661013 | Fragment-based lead generation | Preclinical | [181] |
|                  | S63845    | Structure-based design | Preclinical | [182] |
|                  | AMG176    | Structure-based design | Phase I | [183] |
|                  | AZD5991   | Structure-based design | Phase I | [184] |
|                  | S64315    | Fragment-based lead generation | Phase I/II | [182] |
|                  | S1-6      | Structure-based design | Preclinical | [185] |
|                  | Nap-1     | Derivant of S1-6 | Preclinical | [186] |
**BH3 mimetics inhibit Bcl-xL isoform**

Selective or multi-targeted BH3 mimetics had been developed to antagonize anti-apoptotic proteins of Bcl-2 family through competitively occupying the hydrophobic pockets and thus blocking their anti-apoptotic activity (Fig. 6c) [158]. Table 4 listed BH3-mimetics targeting anti-apoptotic Bcl-2 family proteins selectively. A-1331852 and WHELI-539 selectively targeted to Bcl-xL were all proved to enhance death signals of cancer cells synergistically with radiation or chemotherapy agents [158, 187]. In addition, compounds DT2216 and XZ424 converted from BH3 mimetics by proteolysis-targeting chimera showed improved anticancer potency and reduced cytotoxicity based on E3 ligase mediated degradation of Bcl-xL [162, 163]. However, use of BH3-mimetics in chronic lymphocytic leukaemia and other solid tumours exhibited on-target and off-target effects of Bcl-xL dependent cells and pathways [158, 188–190]. In addition, efficacy of BH3 mimetics was intensely dependent on the membrane localization of Bcl-xL and the nature of interactions between Bcl-xL and pro-apoptotic proteins, which might contribute to a chemotherapeutic resistance of BH3 mimetics [191]. These are still the obstacles for clinical application of BH3 mimetics. Consequently, optimizing the pharmacological effect and concurrent targets of BH3 mimetics to make them promising therapeutic regimens of cancer has been challenging.

**Conclusions**

The inactivation or dysfunction of essential genes caused by defective splicing is emerging as a potential driver of cancer development. Therefore, controlling splicing is of great therapeutic benefit. Dysregulated Bcl-x splicing plays a key role in promoting malignant phenotypes of cancers and weakening the toxicity of treatment. Bcl-xL contributed to the invasion, metastasis, and angiogenesis of cancers. On the contrary, Bcl-xS overexpression was suggested to sensitize apoptosis induced by drugs [129]. Bcl-x splicing correction by SSOs and small molecular modulators showed efficiency in apoptosis regulation of cancer cells. However, the on-targeted toxicity to Bcl-xL-dependent cell types posed challenges to the exploitation and delivery of splicing modulation drugs, which was expected to be addressed by the breakthrough of drug chemistry and carrier system [6]. In addition, the inhibitors of specific splicing factors for Bcl-x splicing correction are needed to be identified. Generally, induction of the balanced ratio of Bcl-xL/Bcl-xS has been shown anti-tumour activity by targeting multiple hallmarks of tumour, but it is still imperative that we understood this biomolecule. It is still unknown what is the intracellular mechanism that induced the preferred splicing of long isoform Bcl-xL. In addition, to discover the interplay of apoptosis and autophagy regulated by Bcl-xL means great significance to Bcl-xL targeted therapy. Moreover, whether the diverse domains of Bcl-xL execute biological functions independently and how does membrane localization affect its biological function in vivo remains unknown. Little is known about the biological function of Bcl-xS beyond its canonical function of lowering apoptosis threshold. In addition to Bcl-x, the anti-apoptotic family members including Bcl-2, Mcl-1 and Bcl-w also have a variety of splice isoforms, however, the elaborate coordination of biological roles played by multiple splice isoforms of Bcl-2 family members is unclear. Thus, much more remains to be researched about this gene in the future.

**Abbreviations**

Bcl-x: Bcl-extra; Bcl-2: B-cell lymphoma 2; SSOs : Splicing-switch oligonucleotide; 5’ SSS: Proximal 5’ splice site; 5’ DSS: Distal 5’ splice site; TM: Transmembrane; IDR: Intrinsically disordered region; MOMP: Mitochondrial outer membrane permeabilization; ROS: Reactive oxygen species; PKC: Protein kinase C inhibitor; GM-CSF: Granulocyte-macrophage colony-stimulating factor; SR: Serine/arginine-rich; hnRNPs: Heterogeneous nuclear ribonucleoproteins; EMT: Epithelial-mesenchymal transition; CML: Chronic myeloid leukaemia; vMO: Vivo-Morpholinol; PS: Phosphorothiate; 2’-O-Me: 2’-O-methyl; 2’-MOE: 2’-O-methoxyethyl; ESS: Exonic splicing silencer; ESE: Exonic splicing enhancer; PP1: Protein phosphatase 1

**Acknowledgements**

Not applicable

**Authors’ contributions**

Study concept and design: Cuixia Di and Hong Zhang. Drafting of the manuscript: Zhihui Dou. Critical revision of the manuscript for important intellectual content: Dapeng Zhao, Xiaohua Chen, Caipeng Xu, Xiaodong Jin, Xuetian Zhang, Yupei Wang, Xiaodong Xie, and Qiang Li. All authors read and approved the final manuscript.

**Funding**

This work was supported by grants from the National Key R&D project of the Chinese Ministry of Science and Technology [2018YFE0205100]; the Key Program of the National Natural Science Foundation of China [U1632270]; the National Natural Science Foundation of China [11675234].

**Availability of data and materials**

Not applicable

**Declarations**

**Consent for publication**

All authors have agreed on the contents of the manuscript.

**Competing interests**

The authors have declared that no competing interest exists.

**Author details**

1Department of Heavy Ion Radiation Medicine, Bio-Medical Research Center, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou 730000, China. 2Key Laboratory of Heavy Ion Radiation Biology and Medicine of Chinese Academy of Sciences, Lanzhou 730000, China. 3College of Life Sciences, University of Chinese Academy of Sciences, Beijing 101408, China. 4School of Nuclear Science and Technology, University of Chinese Academy of Sciences, Beijing 101408, China. 5Medical Genetics Center of Gansu Maternal and Child Health Care Center, Lanzhou 730000, China. 6School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China. 7Advanced Energy Science and Technology Guangdong Laboratory, Huizhou 516029, China.
Received: 24 February 2021  Accepted: 30 May 2021  
Published online: 12 June 2021

References

1. Pistritto G, Trisciuglio D, Ceci C, Garufi A, D’Onaz G. Apoptosis as an anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016;8:603–19.
2. Boite LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, et al. Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597–608.
3. Li M, Wang D, He J, Chen L, Li H. Bcl-x(L): A multifunctional anti-apoptotic protein. Pharmacol Res. 2020;151:105457.
4. Keitel U, Scheel A, Thomale J, Halpale R, Kauflüß S, Scheel C, et al. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget. 2014;5:11178–91.
5. Zhang J, Wang Y, Li SQ, Fang L, Wang XZ, Li J, et al. Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukemia cells and mouse models. Br J Haematol. 2020;189:1141–50.
6. Roberts TC, Langer R, Wood MJ. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;21–22.
7. Irimia M, Blencowe BJ. Alternative splicing: decoding an expansive regulatory code. Annu Rev Biochem. 2020;89:457–86.
8. Lee SC, Abdel-Wahab O. Therapeutic targeting of splicing in cancer. Nat Med. 2016;22:2976–86.
9. Bonnal SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17:457–74.
10. Paschalis A, Sharp A, Welti JC, Neeb A, Raj GV, Luo J, et al. Alternative splicing in prostate cancer. Nat Rev Clin Oncol. 2018;15:663–75.
11. Yang XF, Weber GF, Cantor H. A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells. Immunity. 1997;7:629–39.
12. Fang W, Rivard JJ, Mueller DL, Behrens TW. Cloning and molecular characterization of mouse bcl-x in B and T lymphocytes. J Immunol. 1994;153:488–98.
13. Hossini AM, Gellen CC, Fecker LF, Daniel PT, Kornblihtt AR, et al. Fyn requires HnRNPA2B1 to modulate pre-mRNA alternative splicing. J Biol Chem. 2018;293:10235–44.
14. Xiao X, Littlejohn J, Rodarte C, Zhang L, Martino B, Rascoe P, et al. Up-regulation of Bcl-x by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. Am J Pathol. 2009;175:2207–16.
15. Naro C, Barbagallo F, Chieffi P, Bourgeois CF, Paronetto MP, Sette C. The centrosomal kinase NEK2 is a novel splicing factor kinase involved in cell survival. Nucleic Acids Res. 2014;42:3218–27.
16. Shkultra L, Toutant J, Durand M, Manley JL, Chabot B. SRSF10 connects DNA damage to the alternative splicing of transcripts encoding apoptosis, cell-cycle control, and DNA repair factors. Cell Rep. 2016;17:1990–2003.
17. Chen ZY, Cai L, Zhu J, Chen M, Chen J, Li ZH, et al. Fyn requires RNPA2B1 and Sam68 to synergistically regulate apoptosis in pancreatic cancer. Carcinogenesis. 2011;32:1419–26.
18. Wang Y, Chen D, Qian H, Tsai YS, Shao S, Liu Q, et al. The splicing factor RBM8A controls apoptosis, proliferation, and migration to suppress tumor progression. Cancer Cell. 2014;26:374–89.
19. Inoue A, Yamamoto N, Kimura M, Nishio K, Yamane H, Nakajima K. RBM10 regulates alternative splicing. FEBS Lett. 2014;588:942–7.
20. Pedrotti S, Busà R, Compagnucci C, Sette C. The RNA recognition motif protein RBM11 is a novel tissue-specific splicing regulator. Nucleic Acids Res. 2012;40:1201–32.
21. Zhou A, Au AC, Cho A, Benz EL Jr, Huang SC. Novel splicing factor RBM25 modulates Bcl-x pre-mRNA 5' splice site selection. Mol Cell Biol. 2008;28:5924–36.
22. Massiello A, Roessler JR, Chalffant CE. SAP155 binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5' splice site selection of Bcl-x pre-mRNA. Faseb J. 2006;20:1680–2.
23. Revil T, Toutant J, Shkreta L, Garneau D, Cloutier P, Chabot B. Protein kinase C-dependent control of Bcl-x alternative splicing. Mol Cell Biol. 2007;27:8431–41.
24. Shultz JC, Vu N, Shultz MD, Mbwa MU, Shapiro BA, Chalffant CE. The Proto-oncogene PKCι regulates the alternative splicing of Bcl-x pre-mRNA. Mol Cancer Res. 2012;10:650–9.
25. Vlhuyn MI, Pak ML, Park MA, Thomas D, Lakowski TM, Chalffant CE, et al. PRMT2 interacts with splicing factors and regulates the alternative splicing of Bcl-x. J Biochem. 2017;162:17–25.
26. Weldon C, Dacanay JG, Glockhle V, Boddupalli PVL, Behm-Ansman I, Burley GA, et al. Specific G-quadruplex ligands modulate the alternative splicing of Bcl-x. Nucleic Acids Res. 2018;46:8868–96.
27. Weldon C, Behm-Ansman I, Hurley LH, Burley GA, Brancati E, Eperon IC, et al. Identification of G-quadruplexes in long functional RNAs using 7-deazaguanine RNA. Nat Chem Biol. 2017;13:18–20.
28. Michelle L, Cloutier A, Toutant J, Shkreta L, Thibault P, Durand M, Garneau D, Gendron D, Lapointe E, Couture S, et al. Proteins associated with the exon junction complex also control the alternative splicing of apoptotic regulators. Mol Cell Biol. 2012;32(5):594–67.
49. Zhu LY, Zhu YR, Dai DJ, Wang X, Jin HC. Epigenetic regulation of alternative splicing. Am J Cancer Res. 2018;8:2346–58.

50. Lev Maor G, Yearim A, Ast G. The alternative role of DNA methylation in splicing regulation. Trends Genet. 2015;31:274–80.

51. Khan DH, Gonzalez C, Tailor N, Hamedani MK, Leygue E, Davie JR. Dynamic histone acetylation of H3K4me3 nucleosome regulates MCL1 Pre-mRNA splicing. J Cell Physiol. 2016;231:2196–204.

52. Chen XY, Zhang J, Zhu JS. The role of m(6)A in RNA methylation in human. Mol Cancer. 2019;18:103.

53. Singh R, Gupta SC, Peng WX, Zhou N, Pochampally R, Atti A, et al. Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis. Cell Death Dis. 2016;7:e2626.

54. Zong L, Hattori N, Yaukawa Y, Kimura K, Mori A, Seto Y, et al. LINCO162 confers sensitivity to 5-Aza-2'-deoxycytidine via modulation of an RNA splicing protein, HNRNPH1. Oncogene. 2019;38:281–93.

55. Cui C, Zhai D, Cai L, Duan Q, Xie L, Yu J. Long Noncoding RNA HEIH Promotes Colorectal Cancer Tumorigenesis via Counteracting miR-939. Mediated Transcriptional Repression of Bcl-xl. Cancer Res Treat. 2018;50:992–1008.

56. Elmoro S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.

57. Camero BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395–417.

58. Golder S, Khaniani MS, Derakhshian SM, Baradaran B. Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16:1219–44.

59. Schneider P, Tschopp J. Apoptosis induced by death receptors. Pharm Acta Helv. 2000;74:281–6.

60. O'Neill KL, Huang K, Zhang J, Chen Y, Luo X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes Dev. 2016;30:973–88.

61. Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis mechanisms and roles in cancer development and treatment. Asian Pac J Cancer Prev. 2015;16:1219–44.

62. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:1126–32.

63. Amundson SA, Myers TG, Scudiero D, Kitts A, Reed JC, Fornace AJ Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000;60:101–10.

64. Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of Bcl-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16:99–109.

65. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology. 2001;34:55–61.

66. Scherr AL, Gydrina G, Salou M, Radhakrishnan P, Duglova K, Heller A, et al. Bcl-xL is an oncogenic driver in colorectal cancer. Cell Death Dis. 2016;7:e2342.

67. Gayre SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, et al. Targeting Bcl-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. J Biol Chem. 2019;294:875–86.

68. Das A, Martinez Santos JL, Alsharaee M, Porto GB, Infinger UK, Vandergrift WA 3rd, et al. In vitro effect of dovitinib (TK258), a multi-target anxginostag inhibitor on aggressive meningioma cells. Cancer Invest. 2020;38:349–55.

69. Zhou WH, Tang F, Xu J, Wu X, Yang SB, Feng ZY, et al. Low expression of Bcl-2 correlates with poor prognosis of gastric cancer. Autophagy. 2012;8:389–400.

70. Zhong K, Jiao K, Xing Z, Zhang L, Yang J, Xie X, et al. Bcl-xL overexpression and its association with the progression of tongue carcinoma. Int J Clin Exp Pathol. 2014;7:7360–77.

71. Adams CM, Mitra R, Vogel AN, Liu J, Gong JZ, Eschen CM. Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma. Leukemia. 2020;34:947–52.

72. Pettit J, Lo Iacono M, Rosso V, Andreani G, Jovanovski A, Podestà M, et al. Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms. J Cell Mol Med. 2020;24:10978–86.

73. Xeri L, Parc P, Brousset P, Schlaifer D, Hassoun J, Reed JC, et al. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Haematol. 1996;92:900–6.
97. Wu L, Mao C, Ming X. Modulation of Bcl-xL Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells. Biomed Res Int. 2016;2016:7478650.

98. Zhao R, Hu M, Liang S, Wang B, Yu B, Yang G, et al. cEB8 Inhibits the apoptosis and promotes the cell proliferation of glioma cells via the hnRNP A2/B1-mediated alternative splicing of Bcl-xL. J Immunol Exp Med. 2019;12:2775–83.

99. Yu S, Du M, Yin A, Mai Z, Wang Y, Zhao M, et al. Bcl-xL inhibits PINK1/Parkin-dependent mitophagy by preventing mitochondrial Parkin accumulation. Int J Biochem Cell Biol. 2020;122:105720.

100. Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between apoptosis and autophagy. FEBS J. 2011;278:403–13.

101. Xu X, He S, Ma B. Autoantigen and autophagy-related proteins in cancer. Mol Cancer. 2020;19:12.

102. Lin HY, Qiu HJ, Zeng F, Rao HL, Yang GF, Kung HF, et al. Decreased expression of Bcl-1 correlates closely with Bcl-xL expression and poor prognosis of ovarian carcinoma. PLoS ONE. 2013;8:e60516.

103. Kang R, Zeh HJ, Lotze MT, Tang D. The Bcl-1 network regulates autophagy and cell death. Cell Death Differ. 2011;18:571–80.

104. Pattingre S, Tassa A, Xu Q, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antagonistic proteins inhibit Bcl-1-dependent autophagy. Cell. 2005;122:927–39.

105. Huang X, Qi Q, Hua X, Li X, Zhang W, Sun H, et al. Bcl-1, an autophagy-related gene, augments apoptosis in U87 glioblastoma cells. Oncol Rep. 2014;31:1761–7.

106. Wen J, Mai Z, Zhao M, Wang X, Chen T. Full anti-apoptotic function of Bcl-XL complexed with Bcl-1 verified by live-cell FRET assays. Biochem Biophys Res Commun. 2019;511:700–4.

107. Lindqvist LM, Heinlein M, Huang DC, Vaux DL. Prosurvival Bcl-2 family antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2007;128:885–96.

108. Koehler BC, Scherr AL, Lorenz S, Urbanik T, Kautz N, Elssner C, et al. Beyond Bcl-2: A novel mechanism of resistance to chemotherapy-induced apoptosis. Cancer Res. 2014;74:39.

109. Zhi L, Wang W, Yang L, Zhao X, Jiang H, Ma F. RelB regulates Bcl-xl expression and promotes the cell proliferation of glioma cells via the hnRNP A2/B1-mediated alternative splicing of Bcl-xL. J Immunol Exp Med. 2018;18:93.

110. Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 2011;278:403–13.

111. Liu R, Page C, Beiddler DR, Wicha MS, Nuñez G. Overexpression of Bcl-xL promotes chemotherapeutic resistance of mammary tumors in a syngeneic mouse model. Am J Pathol. 1999;155:1861–7.

112. Zeng Y, Xu X, Wang S, Zhang Z, Liu Y, Han K, et al. Ring finger protein 6 promotes breast cancer cell proliferation by stabilizing estrogen receptor alpha. Oncotarget. 2017;8:20103–12.

113. Zoeller J, Vogody A, Taneja K, Tan BY, O’Brien N, Stomann DJ, et al. Neutralization of BCL-2/X(L) enhances the cytotoxicity of T-CKM-1 in vivo. Mol Cancer Ther. 2019;18:1115–26.

114. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:962–75.

115. Wolter KG, Verheugen M, Fernández Y, Nikolovska-Coleska Z, Riblett M, de la Vega CM, et al. Therapeutic window for melanoma treatment provided by selective effects of the prostates against Bcl-2 proteins. Cell Death Differ. 2007;14:1605–16.

116. Sumantvan NV, Ealovega MW, Nuñez G, Clarke MF, Wicha MS. Overexpression of Bcl-xS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res. 1995;55:2507–10.

117. Streffer JR, Rimmer A, Reeger J, Naumann U, Rodemann HP, Weller M. BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells. J Neurooncol. 2002;56:43–9.

118. Snik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichtsans J, et al. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry. 1999;67:763–8.

119. Li JF, Li YY, Jin W, Yang Q, Shao ZM, Tian XS. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. J Exp Clin Cancer Res. 2012;31:102.

120. Zhou L, Zhu B, Yang L, Zhao X, Jiang H, Ma F, Reib regulates Bcl-xL expression and the irradiation-induced apoptosis of murine prostate cancer cells. Biomed Res Int. 2014;2014:354–8.

121. Ho JN, Kang GY, Lee SS, Kim J, Bae IH, Hwang SG, et al. Bcl-xL and STAT3 mediate malignant actions of gamma-irradiation in lung cancer cells. Cancer Sci. 2010;101:1417–23.

122. Jung CH, Kim EM, Song JY, Park JK, Um HS. Mitochondrial superoxide dismutase 2 mediates γ-irradiation-induced cancer cell invasion. Exp Mol Med. 2015;47:194–101.

123. Borda C, Mar-Bargues C, Román-Dominguez A, Sanz-Ros J, Gmeino-Malenich L, Inglés M, et al. BCL-xL, a Mitochondrial Protein Involved in Successful Aging: From C. elegans to Human Centenarians. Int J Mol Sci. 2020;21:.

124. Pan J, Li D, Xu Y, Zhang J, Wang Y, Chen M, et al. Inhibition of Bcl-2/xL with ABT-263 selectively kills senescent Type II pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice. Int J Radiat Oncol Biol Phys. 2017;99:533–61.

125. Brinkmann K, Waring P, Glaser SP, Wimmer V, Cottle DL, Tham MS, et al. BCL-xL targets B-cell chronic lymphocytic leukemia cells for apoptosis and promotes the cell proliferation of glioma cells via the hnRNP A2/B1-mediated alternative splicing of Bcl-xL. J Immunol Exp Med. 2018;18:93.

126. Zhou F, Yang Y, Xing D. Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. FEBS J. 2011;278:403–13.

127. Amaraa U, Dingwall JP, Hayes CE. Enforced bcl-xL gene expression restored splice-9 lymphocyte development in BAF-FR mutant mice. J Immunol. 2003;170:4593–600.

128. Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax increases intratumoral effector T cells and anti-tumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2020.

129. Chen S, Li X, Zhang W, ZIM, Xu Y. Inflammatory compound Iopopolysaccharide promotes the survival of GM-CSF cultured dendritic cell via PI3 kinase-dependent upregulation of Bcl-xL. Immunol Cell Biol. 2018;96:912–21.

130. Issa F, Milward K, Goto R, Bets G, Wood KJ, Hester J. Transiently activated human regulatory T cells upregulate BCL-2 expression and acquire a functional advantage in vivo. Front Immunol. 2019;10:8089.

131. Wallin RP, Sundquist VS, Bråthenheim E, Cao Y, Ljunggren HG, Grander A. Antiestrogenic effects of NCX-derived RNAs coexpressed by tumour cell Bcl-xL expression. Scand J Immunol. 2014;79:90–7.

132. Carrington EM, Tarlinton DM, Gray DR, Huntington ND, Zhao Y, Lev AM. The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules. Immunol Cell Biol. 2017;95:870–7.
143. Bauman JA, Li SD, Yang A, Huang L, Kole R. Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res. 2010;38:8348–56.

144. Zhang N, Pears JI, Yang P, Tyrell J, Roberts J, Kole R, et al. The importance of Bcl-xL in the survival of human RPE cells. Invest Ophthalmol Vis Sci. 2007;48:3846–53.

145. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-x through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol. 1999;17:1097–100.

146. Mercante DR, Bortner CD, Cidlowski JA, Kole R. Modification of alternative splicing of Bcl-xL pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death. J Biol Chem. 2001;276:16411–17.

147. Mercante DR, Moler HL, Kole R. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents. J Biol Chem. 2002;277:49574–82.

148. Subbottina E, Kogarli SR, Hodgson-Zingman DM, Zingman LV. Morpholino-driven gene editing: A new horizon for disease treatment and prevention. Clin Pharmacol Ther. 2016;99:21–5.

149. Corrionero A, Mihana B, Valscarel J. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug splicestatin A. Genes Dev. 2011;25:445–59.

150. Han T, Gorski M, Gaskill N, Capota E, Kim J, Ting TC, et al. Anticancer sulfonamides target formation by inducing RRM3 degradation via recruitment to DCAF15. Science. 2017;356.

151. Mahfoafia TJ, Mbeli M, Yacqub-Usman K, Hendren A, Haigh DB, Blackley Z, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in antagoptimot B-cell lymphoma. Cancer Res. 2012;26:6535–72.

152. Makhafola TJ, Mbele M, Yacqub-Usman K, Hendren A, Haigh DB, Blackley Z, et al. Anti-tumor activity of splice-biology. Leukemia. 2019;33:1360–72.

153. Kizlo JA, Sun J, Doo J, Sung SS, Takahashi Y, Yin H, et al. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-XL, Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bid-dependent manner. J Biol Chem. 2011;286:9382–92.

154. Ahn CH, Lee WW, Jung YC, Shin JA, Hong KO, Choi S, et al. Antitumor effect of TW-37, a BH3 mimetic in human oral cancer. Lab Anim Res. 2019;35:27.

155. Wei J, Stebbins J, Kita M, Park CH, Lee J, Deng M, et al. The pan-Bcl2 Inhibitor AT101. Actives the Intrinsic Apoptotic Pathway and Causes DNA Damage in Acute Myeloid Leukemia Stem-Like Cells. Target Oncol. 2017;12:677–87.

156. Casara P, Davidson J, Clapper L, Le Toumelin-Braizat G, Vogler M, Bruno A, et al. SS5746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 2018;9:20075–88.

157. Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, et al. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J Med Chem. 2015;58:2180–94.

158. Morel E, Lai K, Liao C, Liu M, Aizmi AS, Aboumeeel A, Mady AS, et al. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2014;13:565–73.

159. Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukaemia. Cancer Discov. 2018;8:1566–81.

160. Safak S, Ince I, Cakmak S, Oncel A, Sahin A, Gozge M, et al. Structure-guided discovery of a selective MCL1 inhibitor with cellular activity. J Med Chem. 2019;62:6913–23.

161. Yi X, Sarker A, Kismali G, Aslan B, Ayres M, Iles LR, et al. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res. 2020;26:3856–67.

162. Tion AE, Belmonte MA, Adam A, Aquila BM, Boisum L, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.

163. Zhang Z, Wu Q, Xie F, Song T, Chang X. 3-Thiomorpholin-4-oxo-8H-acenaphthene (1,2-bipyridin-9-carbonitrile (51) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1) structure-based design and structure-activity relationship studies. J Med Chem. 2011;54:101–5.

164. Wang X, Guo Z, Song T, Zhang X, He NL, Lu P, et al. Proteome-wide identification of on- and off-targets of Bcl-2 inhibitors in native biological systems by using affinity-based probes (AfBPs). ChemBiochem. 2018;19:3212–20.

165. Shen HP, Wu WJ, Xu J, Yang SF, Wu CH, et al. Effects of BI-797 combined with irradiation treatment on uterine cervical cancer cells. Oncol Lett. 2019;18:3428–36.
188. Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17:399.

189. Mérino D, Khaw SL, Glaeser SP, Anderson DJ, Belmont LD, Wong C, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood. 2012;119:5807–16.

190. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29:909–16.

191. Pécot J, Maillet L, Le Pen J, Vuillier C, Trécesson SC, Fétriveau A, et al. Tight sequestration of BH3 Proteins by BCL-xL at subcellular membranes contributes to apoptotic resistance. Cell Rep. 2016;17:3347–58.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.